Summary
Echinomycin is a quinoxaline antibiotic that was originally isolated from Streptomyces echinatus. Based on its antitumor activity against two i.p. implanted murine tumors, the B16 melanoma, and the P388 leukemia, it was brought into clinical trials by the National Cancer Institute. Recent studies on its cytotoxic action have related its antitumor activity with its ability to bifunctionally intercalate with double stranded DNA.
Toxicologic studies were carried out in CDF1 mice and beagle dogs using intravenous injections. For the mice studies the dose ranges were 288–692 mcg/kg (864–2076 mcg/m2) by single bolus, and 112–254 mcg/kg/day (336–762 mcg/m2/day) for five consecutive days. In the dog, dose ranges studied were 8.9–89.4 mcg/kg (178–1788 mcg/m2) by single bolus, and 3.4–33.5 mcg/kg/day (68–670 mcg/m2/day) for five consecutive days. The major toxic effects were found in the gastrointestinal, hepatic, and lymphoreticular systems. These were reversible at all but the highest dose, in dogs that had been treated for five consecutive days.
Phase I clinical trials using various intravenous schedules were sponsored by the National Cancer Institute. Nausea, vomiting, reversible liver enzyme abnormalities, and allergic reactions were the most common toxicities encountered. Based on results from these studies, the National Cancer Institute has recently begun phase II trials in a broad range of diseases. These trials will further characterize echinomycin's toxic effects and its antitumor activity.
Similar content being viewed by others
References
Corbaz R, Ettlinger L, Gaumann E, Keeller-Schierlein W, Kradolfer F, Neipp L, Prelog V, Reusser P, Zahner H: [Metabolic products of actinomycetes. VII. Echinomycin] Helv Chim Acta 40:199–204, 1957
Bhatia MC, Thyagarojan TR, Srivastova OP, Anand N, Vora VC: Quinoxaline antibiotics from a Streptomyces species. Indian J Chem 1:277–278, 1963
Yoshida T, Katagiri K, Yokozawa S: Studies on quinoxaline antibiotics II. Isolation and properties of quinomycin A, B, and C. J Antibiotics 14:330–334, 1961
Tsunodo A: Chemoprophylaxis of poliomyelitis in mice with quinomycin. (Studies on the antibiotic substances from actinomycetes, XLVI). J Antibiotics 15:60–66, 1962
Sato K, Yoshida T, Katagiri K: Inhibition of RNA synthesis in Escherichia coli protoplasts by quinomycins A and C. J Antibiotics 20:188–189, 1967
Katagiri K, Sugiura K: Antitumor action of the quinoxaline antibiotics. Antimicrob Agents Chemother, (1961): pp. 162–168, 1961
Matsuura S: Studies on quinoxaline antibiotics IV. Selective antitumor activity of each quinoxaline antibiotic. J Antibiotics 18:43–46, 1965
Clinical Brochure for Echinomycin, August 1982. Division of Cancer Treatment, National Cancer Institute
Cobb WR, Bogden AE, Reich SD, Griffin TW, Kelton DE, LePage DJ: Activity of two phase I drugs N-methylformamide (NSC-3051) and Echinomycin (NSC-526417) against fresh surgical explants of human tumors in the 6-day subrenal capsule (SRC) assay. Invest New Drugs 1:5–9, 1983
Lathan B, Von Hoff DD: Cytotoxic activity of echinomycin in a human tumor cloning system. Cancer Drug Deliv I:191–198, 1984
Ward DC, Reich E, Goldberg IH: Base specificity in the interaction of polynucleotides with antibiotic drugs. Science 149:1259–1263, 1965
Waring MJ, Wakelin LPG: Echinomycin. A bifunctional intercalating antibiotic. Nature 252:653–657, 1974
Waring M, Makoff A: Breakdown of pulse-labeled ribonucleic acid and polysomes in Bacillus megaterim. Actions of streptolydigin, echinomycin, and triostins. Mol Pharmacol 10:214–224, 1974
Hale EF, Candliffe E, Reynolds PE, Richmond MH, Waring MJ (eds): The Molecular Basis of Antibiotic Action. Wiley Publishing Company, London, 1972, pp. 173–277
Van Dyke MM, Dervan PB: Echinomycin binding sites on DNA. Science 225:1122–1127, 1984
Wakelin LPG, Waring MJ: The binding of echinomycin to deoxyribonucleic acid. Biochem J 157:721–740, 1976
Costantino P, De Santis P, Ughetto G: Circular dichroism studies on the echinomycin — DNA complex. FEBS Lett 88:349–352, 1978
Wang AHJ, Ughetto G, Quigley GJ, Hakoshima T, Van der Marcel GA, Van Bloom JH, Rich A: The molecular structure of a DNA-triostin A complex. Science 225:1115–1121, 1984
Huang CH, Mirabelli CK, Mong S, Crooke ST: Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). Cancer Res 43:2718–2724, 1983
Rao GN, Boysen B, Thompson G, Glaza S, Dickie B, Palmer T, Greenspun K: Preclinical intravenous toxicity study of echinomycin (NSC-526417) in CDF1 mice and beagle dogs. Report No. RAL 82/1092, March 22, 1982. PB83-114298, US Dept Com Natl Tech Inf Serv
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Foster, B.J., Clagett-Carr, K., Shoemaker, D.D. et al. Echinomycin: The first bifunctional intercalating agent in clinical trials. Invest New Drugs 3, 403–410 (1985). https://doi.org/10.1007/BF00170766
Issue Date:
DOI: https://doi.org/10.1007/BF00170766